HealthEquity, Inc. (NASDAQ:HQY) Receives Consensus Rating of “Buy” from Brokerages

HealthEquity, Inc. (NASDAQ:HQY) has received a consensus recommendation of “Buy” from the eleven research firms that are presently covering the stock, Marketbeat reports. Eleven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $96.17.

Several brokerages have commented on HQY. Bank of America lifted their price objective on shares of HealthEquity from $93.00 to $97.00 and gave the stock a “buy” rating in a research report on Wednesday, March 20th. Barrington Research reiterated an “outperform” rating and issued a $100.00 price objective on shares of HealthEquity in a research note on Friday, March 22nd. JMP Securities initiated coverage on HealthEquity in a research report on Thursday, April 4th. They issued a “mkt outperform” rating and a $101.00 target price for the company. JPMorgan Chase & Co. upped their price target on HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. Finally, Royal Bank of Canada lifted their price objective on HealthEquity from $90.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, March 20th.

HealthEquity Stock Performance

Shares of HealthEquity stock opened at $80.30 on Tuesday. The business’s fifty day simple moving average is $81.01 and its 200 day simple moving average is $74.49. The company has a current ratio of 4.76, a quick ratio of 4.76 and a debt-to-equity ratio of 0.43. HealthEquity has a 12 month low of $48.86 and a 12 month high of $84.49. The firm has a market capitalization of $6.89 billion, a P/E ratio of 125.47, a price-to-earnings-growth ratio of 1.31 and a beta of 0.53.

HealthEquity (NASDAQ:HQY) last announced its earnings results on Tuesday, March 19th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.42 by $0.08. The firm had revenue of $262.39 million during the quarter, compared to analyst estimates of $258.56 million. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. As a group, analysts anticipate that HealthEquity will post 2.12 EPS for the current year.

Insider Buying and Selling

In other HealthEquity news, EVP Delano Ladd sold 2,558 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $82.59, for a total transaction of $211,265.22. Following the completion of the transaction, the executive vice president now owns 47,438 shares of the company’s stock, valued at $3,917,904.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Delano Ladd sold 2,558 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $82.59, for a total value of $211,265.22. Following the transaction, the executive vice president now owns 47,438 shares in the company, valued at $3,917,904.42. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Jon Kessler sold 33,765 shares of the stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $79.81, for a total value of $2,694,784.65. Following the sale, the chief executive officer now owns 126,635 shares in the company, valued at $10,106,739.35. The disclosure for this sale can be found here. Insiders have sold a total of 71,322 shares of company stock valued at $5,682,895 over the last ninety days. Company insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HQY. Cape Investment Advisory Inc. purchased a new position in HealthEquity during the fourth quarter valued at $27,000. Rise Advisors LLC purchased a new position in HealthEquity during the first quarter valued at $28,000. McGlone Suttner Wealth Management Inc. purchased a new position in HealthEquity during the fourth quarter valued at $29,000. YHB Investment Advisors Inc. purchased a new position in HealthEquity during the first quarter valued at $40,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in HealthEquity during the third quarter valued at $41,000. 99.55% of the stock is currently owned by institutional investors.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.